TrkB
TrkB (tropomyosin receptor kinase B), encoded by NTRK2, is a neurotrophic tyrosine kinase receptor that mediates the cellular actions of brain-derived neurotrophic factor (BDNF) and contributes to neuronal differentiation, neuroplasticity, and homeostasis[1][2]. Mechanistically, ligand-induced activation of full-length TrkB (TrkB.FL) triggers receptor autophosphorylation and engages intracellular signaling pathways including PI3K, MAPK/ERK, and PLCγ, thereby supporting neurotrophic responses and synaptic function[3][4]. Alternative splicing of NTRK2 generates distinct receptor isoforms, including TrkB.FL and truncated variants such as TrkB.T1, TrkB.T2, and TrkB-T-ShC, which lack the tyrosine kinase domain and therefore differ fundamentally in signaling capacity[2][5]. Compared with TrkB.FL, TrkB.T1 is the major truncated isoform in the adult brain and can negatively regulate full-length receptor signaling through dominant-inhibitory mechanisms while also exhibiting independent biological activities[5][4]. Altered TrkB isoform balance has been associated with neurodegeneration, ischemic injury, amyotrophic lateral sclerosis, spinal muscular atrophy, psychiatric disorders, and cognitive dysfunction, highlighting the importance of isoform-specific regulation in disease biology[2][6][4][7]. In experimental systems, modulation of BDNF-TrkB signaling and manipulation of TrkB isoform expression are widely used to investigate neuronal survival, differentiation, synaptic plasticity, and disease mechanisms, making TrkB a valuable target for mechanistic and translational neuroscience research[3][5][4].
References:
- [1]. Duarte-Ruiz M, et al. Regulation of NTRK2 alternative splicing by PRPF40B controls neural differentiation and synaptic plasticity. Cell Death Dis. 2025 Dec 8;17(1):73. [Content Brief]
- [2]. Li Y, et al. Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours. J Pathol Clin Res. 2023 Mar;9(2):89-99. [Content Brief]
- [3]. TrkB gene information from NCBI.
- [4]. Rabezanahary H, et al. Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada. Heliyon. 2024 May 21;10(10):e31026. [Content Brief]
- [5]. Tessarollo L, et al. TrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions. Front Neurosci. 2022 Mar 7;16:847572. [Content Brief]
- [6]. Vidaurre OG, et al. Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity. Cell Death Dis. 2012 Jan 19;3(1):e256. [Content Brief]
- [7]. Chang C, et al. Recent advances in deciphering hippocampus complexity using single-cell transcriptomics. Neurobiol Dis. 2023 Apr;179:106062. [Content Brief]
-
TrkB Related Products (49)
Related Products (49)
-
Antibodies (2)
-
PF-07245303
0 ImagesCat. No.: HY-182335CAS No.: 2655556-75-3PF-07245303 is a ITK/TRK inhibitor. PF-07245303 reduces the production of inflammatory cytokines such as IL-4 and IFNγ, and inhibits the phosphorylation of PLCγ1. PF-07245303 inhibits nerve growth factor-induced basophil activation and the phosphorylation of TRKA. PF-07245303 reduces oxazolone-induced ear swelling in mouse ear tissues. PF-07245303 is applicable to research related to atopic dermatitis.
-
TrkB agonist-1
0 ImagesTrkB agonist-1 is an orally active, blood-brain barrier-permeable TrkB agonist. TrkB agonist-1 activates the TrkB signaling pathway and its downstream AKT and ERK/MAPK pathways via its released parent compound, reduces AEP enzyme activity and inhibits its activation, and simultaneously suppresses the production of pro-inflammatory cytokines. TrkB agonist-1 is used in the research of Alzheimer's disease.
-
YTB53
0 ImagesCat. No.: HY-184431YTB53 is a MNK1 and MNK2 inhibitor with IC50s of 37 nM and 9 nM, respectively. YTB53 inhibits PDGFRα, TRKB and FLT3 in leukemia cells. YTB53 induces cell cycle arrest, apoptosis, pyroptosis, and mitochondrial dysfunction. YTB53 exhibits antiangiogenic effects. YTB53 can be used for the study of acute myeloid leukemia (AML).
-
TRK II-IN-1
0 ImagesCat. No.: HY-151945CAS No.: 2904690-41-9
-
JND4135
0 ImagesCat. No.: HY-126287CAS No.: 2366216-76-2JND4135 is a Type II TRK inhibitor with IC50 values of 2.79, 3.19, and 3.01 nM against TRKA, TRKB, TRKC, respectively. JND4135 can overcome resistance from TRK xDFG and other mutant forms in the BaF3 stable model, inhibiting phosphorylation of both WT and xDFG mutant TRKs, along with their downstream signaling molecules. JND4135 can induce G0/G1 phase arrest and apoptosis in BaF3–CD74-TRKA-G667C cells. JND4135 shows tumor growth inhibition activity in the BaF3-CD74-TRKA-G667C mouse xenograft model.
-
Pan-Trk-IN-3
0 ImagesCat. No.: HY-144069CAS No.: 2763637-66-5Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-Trk and their drug-resistant mutants with IC50 values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against TrkA, TrkB, TrkC, TrkAG595R, TrkAG667C, TrkAG667S, TrkAF589L and TrkCG623R, respectively. Pan-Trk-IN-3 displays excellent antitumor activity and induces apoptosis.
-
IHMT-TRK-284
0 ImagesCat. No.: HY-146697CAS No.: 2416844-79-4
-
NMS-P626
0 ImagesCat. No.: HY-164514CAS No.: 942471-37-6NMS-P626 is an inhibitor of TRKA, TRKB, and TRKC, with IC50 values of 8 nM, 7 nM, and 3 nM, respectively. NMS-P626 inhibits the growth of KM12 cells by suppressing the phosphorylation of TPM3-TRKA and downstream signaling in KM12 cells, with an IC50 of 19 nM for KM12 cells. NMS-P626 can be used in colorectal cancer research.
-
BNN-20
0 ImagesBNN-20 is a synthetic microneurotrophin that mimics brain-derived neurotrophic factor (BDNF) and exhibits area-specific pleiotropic neuroprotective and pro-neurogenic effects. BNN-20 can be utilized in research related to Parkinson's disease.
